Glpld.org

Site Inspections

Overview & More informations

GLP Life Sciences, Inc. (GLP) is a clinical-stage biotechnology company focused on the development and commercialization of novel therapeutics for chronic liver diseases and certain types of cancer. GLP's lead product candidate, avasopasem sodium, is a first-in-class, investigational new drug that targets the underlying causes of liver fibrosis and cirrhosis, and has the potential to improve outcomes for patients with chronic liver diseases. GLP's other product candidates include GLP-1005, an oral small molecule for the treatment of solid tumors, and GLP-1010, an immunotherapy for the treatment of liver cancer.

GLP was founded in 2014 and is headquartered in La Jolla, California. The company has raised over $100 million in funding from investors such as RA Capital Management, Redmile Group, and OrbiMed Advisors. GLP is led by a team of experienced biotechnology executives with a track record of success in drug development and commercialization.

GLP's lead product candidate, avasopasem sodium, is a first-in-class, investigational new drug that targets the underlying causes of liver fibrosis and cirrhosis. Avasopasem sodium is a small molecule that inhibits the activity of tissue transglutaminase 2 (TG2), an enzyme that plays a key role in the development of liver fibrosis and cirrhosis. In preclinical studies, avasopasem sodium has been shown to reduce liver fibrosis and improve liver function in animal models of chronic liver disease.

GLP is currently conducting a Phase 2 clinical trial of avasopasem sodium in patients with non-alcoholic steatohepatitis (NASH), the most common cause of chronic liver disease in the United States. The trial is designed to evaluate the safety and efficacy of avasopasem sodium in reducing liver fibrosis and improving liver function in patients with NASH. GLP plans to initiate a Phase 3 clinical trial of avasopasem sodium in patients with NASH in 2023.

GLP's other product candidates include GLP-1005, an oral small molecule for the treatment of solid tumors, and GLP-1010, an immunotherapy for the treatment of liver cancer. GLP-1005 is currently in Phase 1 clinical trials, and GLP-1010 is in preclinical development.

GLP is a clinical-stage biotechnology company with a promising pipeline of novel therapeutics for chronic liver diseases and certain types of cancer. The company's lead product candidate, avasopasem sodium, has the potential to improve outcomes for patients with chronic liver diseases. GLP is well-funded and has a team of experienced biotechnology executives with a track record of success in drug development and commercialization.

Domains Expiration Date Updated